SELLAS Stock More Than Doubles After Cancer Vaccine Cuts Leukemia Death Risk by 41% in Pivotal Phase 3 Trial
Shares of SELLAS Life Sciences Group Inc. more than doubled on Tuesday after the company said its experimental cancer vaccine significantly extended survival in a late-stage trial in patients with acute myeloid leukemia. The result is a long-awaited win for the small New York-based biotech.
The stock was up $10.36, or 138.69%, at $17.83 on the Nasdaq at 9:50 a.m. EST, shortly after the opening bell. Premarket gains had been steeper: several financial news outlets reported the shares up more than 200% before the open. Trading volume was heavy.
SELLAS said its pivotal Phase 3 REGAL trial of galinpepimut-S, known as GPS, met its primary goal of overall survival.
Patients who received GPS lived a median of 24.0 months, compared with 14.7 months for patients who received the best available treatment chosen by their doctors. That is a difference of 9.3 months.
The hazard ratio was 0.59, meaning a 41% lower risk of death for patients on the vaccine. The result had a two-sided p-value of 0.035, below the usual threshold for statistical significance.
"REGAL has delivered on its primary objective, demonstrating a statistically significant and clinically meaningful improvement in overall survival for patients with AML who have very limited options after achieving a second remission," Chief Executive Officer Angelos Stergiou said in a statement.
A hard-to-treat population
The global, randomized, open-label trial enrolled 126 adults with AML. All had reached a second or later remission after further rounds of treatment but could not undergo a stem cell transplant,........
